Levodopa Gel Composition for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders like Parkinson's disease face challenges such as fluctuating drug levels, side effects, and stability issues with pharmaceutical compositions.
Innovation Solution
A pharmaceutical gel composition for intra-intestinal administration, comprising a combination of a dopamine replacement agent (e.g., levodopa), a dopamine decarboxylase inhibitor (DDI) (e.g., carbidopa), and a catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone), which provides stable plasma drug levels and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered as a dopamine replacement agent, then dopamine concentration in the brain is restored, but plasma drug levels fluctuate and side effects occur
Solution Approach 1:
The patent combines levodopa with a dopamine decarboxylase inhibitor (DDI) and a COMT inhibitor in a single pharmaceutical composition. This combination merges multiple mechanisms of action to stabilize plasma drug levels: the DDI prevents peripheral decarboxylation of levodopa, while the COMT inhibitor prevents methylation of levodopa and its metabolites, thereby maintaining consistent levodopa availability and reducing fluctuations in plasma concentration.
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing levodopa, DDI, and COMT inhibitor in specific ratios. This composite formulation integrates multiple functional components to achieve both therapeutic efficacy and plasma level stability, with the composite nature of the formulation allowing coordinated action of all three agents to maintain optimal drug levels.
2Reliability
If levodopa is administered to treat Parkinson's disease, then dopamine concentration is restored, but side effects occur
Solution Approach 1:
The patent extracts and inhibits harmful peripheral metabolism of levodopa by incorporating a dopamine decarboxylase inhibitor that specifically blocks peripheral decarboxylation. This extraction of the harmful metabolic pathway reduces side effects caused by peripheral dopamine formation while preserving the beneficial central nervous system effect of levodopa conversion to dopamine in the brain.
Solution Approach 2:
The COMT inhibitor acts as an intermediary that prevents the formation of harmful metabolites through methylation of levodopa and its active metabolites. By blocking this intermediary metabolic pathway, the composition reduces the formation of inactive or harmful metabolites that contribute to side effects, while allowing the primary therapeutic pathway to remain intact.
3Ease of manufacture
If conventional pharmaceutical compositions are used, then treatment is provided, but stability issues occur
Solution Approach 1:
The patent optimizes the concentration ratios of levodopa, DDI, and COMT inhibitor in the pharmaceutical composition. By carefully adjusting these parameters (concentrations), the formulation achieves both manufacturability and enhanced stability. The specific ratio parameters are designed to prevent degradation interactions between the components while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves stable plasma drug levels, reduces side effects, and enhances bioavailability of levodopa, leading to improved therapeutic outcomes for patients with Parkinson's disease.
Implementation Method 1
a dopamine decarboxylase inhibitor (DDI) (e.g., carbidopa)... which provides stable plasma drug levels and improved bioavailability
Implementation Method 2
a catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone)... which provides stable plasma drug levels and improved bioavailability
Implementation Method 3
A pharmaceutical gel composition for intra-intestinal administration... enhances bioavailability of levodopa
Data Source
AI summary
A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDD), and (ii) a COMT inhibitor.